Pharmaceutical care of a critical patient with acute heart failure after PCI by clinical pharmacists

LI Linli; ZHANG Peilian; ZHANG Jiali

doi:10.6039/j.issn.1001-0408.2023.18.17

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care of a critical patient with acute heart failure after PCI by clinical pharmacists

更新时间：2025-09-26

- Pharmaceutical care of a critical patient with acute heart failure after PCI by clinical pharmacists
- ZHONGGUO YAOFANG Vol. 34, Issue 18, Pages: 2269-2273(2023)
- 作者机构：
  
  1.浙江大学医学院附属第二医院药剂科，杭州　310052
  2.河北医科大学第三医院临床药学部，石家庄　050051
  3.晋江市中医院医疗服务部，福建泉州　362211
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.18.17
  CLC： R969.3
- Received：12 April 2023，
  
  Revised：2023-08-23，
  
  Accepted：25 August 2023，
  
  Published：30 September 2023
- 稿件说明：
移动端阅览
黎林丽,张培莲,张佳丽.临床药师参与1例PCI术后合并急性心力衰竭患者的药学监护[J].中国药房,2023,34(18):2269-2273.

LI Linli,ZHANG Peilian,ZHANG Jiali.Pharmaceutical care of a critical patient with acute heart failure after PCI by clinical pharmacists[J].ZHONGGUO YAOFANG,2023,34(18):2269-2273.
黎林丽,张培莲,张佳丽.临床药师参与1例PCI术后合并急性心力衰竭患者的药学监护[J].中国药房,2023,34(18):2269-2273. DOI： 10.6039/j.issn.1001-0408.2023.18.17.

LI Linli,ZHANG Peilian,ZHANG Jiali.Pharmaceutical care of a critical patient with acute heart failure after PCI by clinical pharmacists[J].ZHONGGUO YAOFANG,2023,34(18):2269-2273. DOI： 10.6039/j.issn.1001-0408.2023.18.17.

摘要

目的

探讨临床药师在经皮冠状动脉介入（PCI）术后合并急性心力衰竭患者治疗过程中发挥的作用，为此类患者的药物治疗和监护提供参考。

方法

临床药师参与1例PCI术后合并急性心力衰竭患者的治疗过程，结合国内外文献，协助医师共同制定个体化用药方案：建议给予注射用亚胺培南西司他丁钠抗感染，根据肾功能调整药物剂量，并及时进行降阶梯治疗；选用左乙拉西坦片预防癫痫；对可能由阿托伐他汀钙片引起的横纹肌溶解进行鉴别诊断及对症处理；同时进行全程的药学监护。

结果

医师采纳了临床药师的建议。该患者的急性心力衰竭症状得到控制，肺部感染情况好转，不良反应症状缓解，顺利转出重症监护病房。

结论

对于重症患者，给予亚胺培南西司他丁抗感染治疗时，临床药师应根据患者肾功能调整剂量并警惕其可能的神经毒性；在阿托伐他汀钙片治疗过程中，临床药师应综合分析患者是否存在发生横纹肌溶解的风险；对已发生的不良反应，应及时对症处理，以保障患者用药的安全性和有效性。

Abstract

OBJECTIVE

To explore the role of clinical pharmacists in the treatment of critical patients with acute heart failure after percutaneous coronary intervention （PCI）， and to provide reference for drug treatment and monitoring of such patients.

METHODS

Clinical pharmacists participated in the treatment of a critical patient with acute heart failure after PCI， and assisted physicians to jointly develop individualized medication plans based on domestic and foreign literature： it was suggested to give imipenem and cilastatin for anti-infective therapy， adjust drug dose according to renal function， and timely descend step therapy； Levetiracetam tablets were selected to prevent epilepsy； the differential diagnosis and treatment of rhabdomyolysis possibly caused by Atorvastatin calcium tablets were performed； the whole process of pharmaceutical care was conducted.

RESULTS

Physicians adopted the suggestions of clinical pharmacists. The acute heart failure of the patient was controlled， the pulmonary infection was improved， the adverse reaction symptoms were relieved， and the patient was successfully transferred out of the ICU.

CONCLUSIONS

For severe patients， when giving imipenem and cilastatin for anti-infection treatment，the clinical pharmacist should adjust the dose according to the patient’s renal function and be alert to the possible neurotoxicity. During the treatment with Atorvastatin calcium tablets，the clinical pharmacist should comprehensively analyze the risk of rhabdomyolysis. For the adverse reactions that have occurred， clinical pharmacist should promptly address symptomatic issues to ensure the safety and effectiveness of medication for patients.

关键词

Keywords

references

中华医学会，中华医学会杂志社，中华医学会全科医学分会，等 . 冠心病心脏康复基层指南：2020年 [J ] . 中华全科医师杂志， 2021 ， 20 （ 2 ）： 150 - 165 .

GHEORGHIADE M ， ZANNAD F ， SOPKO G ， et al . Acute heart failure syndromes：current state and framework for future research [J ] . Circulation ， 2005 ， 112 （ 25 ）： 3958 - 3968 .

中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J ] . 中华心血管病杂志， 2018 ， 46 （ 10 ）： 760 - 789 .

程燕，车炜，于晓龙，等 . 老年心力衰竭患者出院后2年预后及影响因素 [J ] . 临床心血管病杂志， 2017 ， 33 （ 12 ）： 1206 - 1209 .

中华医学会，中华医学会杂志社，中华医学会全科医学分会，等 . 急性心力衰竭基层诊疗指南：2019年 [J ] . 中华全科医师杂志， 2019 ， 18 （ 10 ）： 925 - 930 .

国家卫生计生委合理用药专家委员会，中国药师协会 . 心力衰竭合理用药指南：第2版 [J/OL ] . 中国医学前沿杂志（电子版）， 2019 ， 11 （ 7 ）： 1 - 78 （ 2019-07-20 ）[ 2023-03-12 ] . https：//kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C-44YLTlOAiTRKibYlV5Vjs7iLik5jEcCI09uHa3oBxtWo-NDqD-scQal_YmpfsnodCkfLmSeKTYmYzP_glclOBSg-C&uniplatform=NZKPT. DOI：10.12037/YXQY.2019.07-01 https://kns.cnki.net/kcms2/article/abstract?v=3uoqIhG8C-44YLTlOAiTRKibYlV5Vjs7iLik5jEcCI09uHa3oBxtWo-NDqD-scQal_YmpfsnodCkfLmSeKTYmYzP_glclOBSg-C&uniplatform=NZKPT.DOI:10.12037/YXQY.2019.07-01 .

王春艳，刘慧峰 . 注射用重组人脑利钠肽治疗急性心肌梗死并心力衰竭的疗效及其对心功能的影响 [J ] . 临床合理用药杂志， 2023 ， 16 （ 12 ）： 1 - 3 .

朱克群，冯东杰 . 重症监护病房细菌流行分布及耐药性监测研究 [J ] . 实用医学杂志， 2011 ， 27 （ 8 ）： 1480 - 1482 .

余跃天，马朋林 . 重症监护病房多重耐药菌防控：指南与实践 [J ] . 中华医学杂志， 2019 ， 99 （ 25 ）： 1945 - 1948 .

中华医学会呼吸病学分会感染学组 . 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南：2018年版 [J ] . 中华结核和呼吸杂志， 2018 ， 41 （ 4 ）： 255 - 280 .

CANNON J P ， LEE T A ， CLARK N M ， et al . The risk of seizures among the carbapenems：a meta-analysis [J ] . J Antimicrob Chemother ， 2014 ， 69 （ 8 ）： 2043 - 2055 .

WANLEENUWAT P ， SUNTHARAMPILLAI N ， IWANOWSKI P . Antibiotic-induced epileptic seizures：mechanisms of action and clinical considerations [J ] . Seizure ， 2020 ， 81 ： 167 - 174 .

NARANJO C A ， BUSTO U ， SELLERS E M ， et al . A method for estimating the probability of adverse drug reactions [J ] . Clin Pharmacol Ther ， 1981 ， 30 （ 2 ）： 239 - 245 .

NEWMAN C B ， PREISS D ， TOBERT J A ， et al . Statin safety and associated adverse events：a scientific statement from the American Heart Association [J ] . Arterioscler Thromb Vasc Biol ， 2019 ， 39 （ 2 ）： e38 - e81 .

中国抗癫痫协会 . 临床诊疗指南：癫痫病分册 [M ] . 2版 . 北京：人民卫生出版社， 2015 ： 59 - 66 .

中国医师协会神经内科医师分会癫痫疾病专业委员会 . 中国基因性全面性癫痫临床诊治实践指南 [J ] . 中华神经医学杂志， 2020 ， 19 （ 10 ）： 973 - 976 .

CHEN I L ， LEE C H ， HSIAO S C ， et al . Interactions between carbapenems and valproic acid among the patients in the intensive care units [J ] . J Crit Care ， 2021 ， 62 ： 151 - 156 .

SEKIMOTO H ， RIKITAKE Y . Efficacy and safety of levetiracetam in Japanese epilepsy patients：a retrospective cohort study [J ] . J Clin Pharm Ther ， 2019 ， 44 （ 6 ）： 912 - 923 .

SAFITRI N ， ALAINA M F ， PITALOKA D A E ， et al . A narrative review of statin-induced rhabdomyolysis： molecular mechanism，risk factors，and management [J ] . Drug Healthc Patient Saf ， 2021 ， 13 ： 211 - 219 .

TANAKA S ， SAKAMOTO K ， YAMAMOTO M ， et al . Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers [J ] . J Pharmacol Sci ， 2010 ， 114 （ 4 ）： 454 - 463 .

ATTARDO S ， MUSUMECI O ， VELARDO D ， et al . Statins neuromuscular adverse effects [J ] . Int J Mol Sci ， 2022 ， 23 （ 15 ）： 8364 .

Views

158

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis

Expert consensus on rational medication management of targeted PI3K/Akt/mTOR inhibitors in breast cancer

Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

Pharmaceutical care of anti-infective treatment for a case of pulmonary infection due to Alternaria alternata after renal transplantation

Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

Related Author

ZHANG Qinghua

HE Liting

Writing Group of Expert Consensus on Rational Medication Management of Targeted PI3K/Akt/mTOR Inhibitors in Breast Cancer

任天舒

赵庆春

ZHANG Ming

YU Lu

WU Xudong

Related Institution

Dept. of Pharmacy， Jiangmen Central Hospital

Dept. of Internal Medicine， Zhonggongmiao Community Hospital of Ningbo Yinzhou District No.2 Hospital Medical Community

Dept. of Clinical Pharmacy， Ningbo Yinzhou District No.2 Hospital

Dept. of Pharmacy， Tangshan Maternal and Child Health Hospital

Dept. of Pharmacy， Tianjin Anding Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰